Anti-Taq DNA polymerase antibody and its uses

A novel binding protein with antigen-binding domains addresses non-specific amplification and stability issues in Taq DNA polymerase by blocking its activity at room temperature and activating it at high temperatures, improving PCR specificity and stability.

JP7590964B2Active Publication Date: 2024-11-27FAPON BIOTECH INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021526467
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-20
Filing Date
2019-10-01
Publication Date
2024-11-27
Estimated Expiration
2039-10-01

AI Technical Summary

Technical Problem

Taq DNA polymerase used in PCR reactions causes non-specific amplification and primer dimer formation due to its constant enzymatic activity at room temperature, leading to stability issues.

Method used

Development of a novel binding protein with specific antigen-binding domains that forms a complex with Taq DNA polymerase, blocking its activity at room temperature and dissociating at high temperatures to initiate PCR amplification, thereby preventing non-specific amplification.

Benefits of technology

The binding protein effectively prevents primer dimer formation and enhances the long-term stability of Taq DNA polymerase by ensuring specific amplification during PCR reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590964000011
    Figure 0007590964000011
  • Figure 0007590964000012
    Figure 0007590964000012
  • Figure 0007590964000001
    Figure 0007590964000001
Patent Text Reader

Abstract

The present invention provides an isolated binding protein comprising a Taq DNA polymerase antigen-binding domain, wherein the antigen-binding domain comprises at least one complementarity determining region selected from CDR-VH1-3 and CDR-VL1-3, or has at least 80% sequence identity with said complementarity determining region and exhibits K activity against Taq DNA polymerase. D ≦8.568×10 -9 The binding protein has an affinity of 100 mol / L and can be used in molecular detection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to a Chinese patent application bearing application number 201811566184.2, filed with the State Intellectual Property Office of China on December 20, 2018, and entitled "Anti-Taq DNA polymerase antibody and its use," the entire contents of which are incorporated herein by reference.

[0002] The present disclosure relates to the fields of biotechnology and medical technology, and in particular to anti-Taq DNA polymerase antibodies and uses thereof. [Background technology]

[0003] Randall K. Saiki et al. isolated and purified Taq DNA polymerase from Thermus aquaticus in 1988. Taq polymerase can withstand high temperatures of over 90°C without losing activity, which is especially important for PCR reactions that require high temperature environments. Therefore, Taq polymerase has replaced DNA polymerase in Escherichia coli, which has been commonly used in PCR reactions. When Taq polymerase is used in PCR reactions, there is no need to add enzymes for each cycle, making PCR technology easier to perform, significantly reducing costs, and becoming more widely used and clinically applicable. However, Taq DNA polymerase has some disadvantages during use. That is, it has certain enzyme properties at room temperature, which leads to non-specific amplification and primer dimer formation in the PCR amplification process, resulting in problems with long-term stability.

[0004] Therefore, with the expanding use of PCR technology and the improvement of the quality requirements for PCR amplification, new methods and technologies have been developed one after another, among which, since the emergence of hot-start enzyme technology, the enzymatic properties of ordinary Taq DNA polymerase have been steadily improved. Currently, the most commonly used methods include antibody-modified hot-start enzymes and chemically modified hot-start enzymes, of which antibody-modified hot-start enzymes are more commonly used.

[0005] The antibody-modified hot-start enzyme is a monoclonal antibody that uses a specific Taq enzyme. When the monoclonal antibody of the specific Taq enzyme binds to Taq DNA polymerase, an antigen-antibody complex is formed, which effectively blocks the activity of Taq DNA polymerase at room temperature and prevents the polymerase from exerting its activity at low temperatures. At high temperatures, the complex dissociates and releases active Taq DNA polymerase before the PCR amplification reaction can begin. This effectively avoids the formation of primer dimers, mitigates the amplification of non-specific products, and improves the long-term stability of Taq DNA polymerase.

[0006] The specificity of the Taq enzyme antibody used for the antibody-modified hot-start enzyme is open to further development. Summary of the Invention [Problem to be solved by the invention]

[0007] The present disclosure relates to an isolated novel binding protein comprising a Taq DNA polymerase antigen-binding domain, and studies are conducted on the production, uses, etc. of the binding protein. [Means for solving the problem]

[0008] The antigen-binding domain comprises at least one complementarity determining region selected from the following amino acid sequences, or has at least 80% sequence identity with the complementarity determining region of the following amino acid sequence and has K for Taq DNA polymerase: D ≦8.568×10 -9It has an affinity of mol / L. The complementarity determining region CDR-VH1 is SV-X1-TF-X2-TYY-X3-Y, where X1 is D, E or N, X2 is S or T, and X3 is I or L; The complementarity determining region CDR-VH2 is G-X1-NPTS-X2-PVF-X3-EK, where X1 is I, V or L, X2 is N or GG, and X3 is D, E or N; The complementarity determining region CDR-VH3 is TRS-X1-X2-RRGYY-X3-DY, where X1 is I, V or L, X2 is I, V or L, and X3 is F or P; The complementarity determining region CDR-VL1 is R-X1-SQDI-X2-NY-X3-N, where X1 is A or G, X2 is N or Q, and X3 is I, V, or L; The complementarity determining region CDR-VL2 is IY-X1-TSRL-X2-SG-X3-P, where X1 is Y or F, X2 is Q, H or N, and X3 is I, V or L; The complementarity determining region CDR-VL3 is QDDT-X1-P-X2-T-X3-G, where X1 is I, V or L, X2 is I, V or L, and X3 is W or F.

[0009] One major advantage is that the binding protein is highly active and has a very high affinity for Taq DNA polymerase.

[0010] In one or more embodiments, In the complementarity determining region CDR-VH1, X3 is I; In the complementarity determining region CDR-VH2, X3 is N; In the complementarity determining region CDR-VH3, X3 is F; In the complementarity determining region CDR-VL1, X1 is A; In the complementarity determining region CDR-VL2, X1 is Y; In said complementarity determining region CDR-VL3, X3 is F.

[0011] In one or more embodiments, X1 is D and X2 is S in the complementarity determining region CDR-VH1.

[0012] In one or more embodiments, X1 is E and X2 is S in the complementarity determining region CDR-VH1.

[0013] In one or more embodiments, X1 is N and X2 is S in the complementarity determining region CDR-VH1.

[0014] In one or more embodiments, X1 is D and X2 is T in the complementarity determining region CDR-VH1.

[0015] In one or more embodiments, X1 is E and X2 is T in the complementarity determining region CDR-VH1.

[0016] In one or more embodiments, X1 is N and X2 is T in the complementarity determining region CDR-VH1.

[0017] In one or more embodiments, X1 is I and X2 is N in the complementarity determining region CDR-VH2.

[0018] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is I and X2 is GG.

[0019] In one or more embodiments, X1 is V and X2 is N in the complementarity determining region CDR-VH2.

[0020] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is V and X2 is GG.

[0021] In one or more embodiments, X1 is L and X2 is N in the complementarity determining region CDR-VH2.

[0022] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is L and X2 is GG.

[0023] In one or more embodiments, X1 is I and X2 is I in the complementarity determining region CDR-VH3.

[0024] In one or more embodiments, X1 is I and X2 is V in the complementarity determining region CDR-VH3.

[0025] In one or more embodiments, X1 is I and X2 is L in the complementarity determining region CDR-VH3.

[0026] In one or more embodiments, X1 is V and X2 is I in the complementarity determining region CDR-VH3.

[0027] In one or more embodiments, in the complementarity determining region CDR-VH3, X1 is V and X2 is V.

[0028] In one or more embodiments, X1 is V and X2 is L in the complementarity determining region CDR-VH3.

[0029] In one or more embodiments, X1 is L and X2 is I in the complementarity determining region CDR-VH3.

[0030] In one or more embodiments, X1 is L and X2 is V in the complementarity determining region CDR-VH3.

[0031] In one or more embodiments, X1 is L and X2 is L in the complementarity determining region CDR-VH3.

[0032] In one or more embodiments, X2 is N and X3 is I in the complementarity determining region CDR-VL1.

[0033] In one or more embodiments, X2 is N and X3 is V in the complementarity determining region CDR-VL1.

[0034] In one or more embodiments, X2 is N and X3 is L in the complementarity determining region CDR-VL1.

[0035] In one or more embodiments, X2 is Q and X3 is I in the complementarity determining region CDR-VL1.

[0036] In one or more embodiments, X2 is Q and X3 is V in the complementarity determining region CDR-VL1.

[0037] In one or more embodiments, X2 is Q and X3 is L in the complementarity determining region CDR-VL1.

[0038] In one or more embodiments, X2 is Q and X3 is I in the complementarity determining region CDR-VL2.

[0039] In one or more embodiments, X2 is Q and X3 is V in the complementarity determining region CDR-VL2.

[0040] In one or more embodiments, X2 is Q and X3 is L in the complementarity determining region CDR-VL2.

[0041] In one or more embodiments, X2 is H and X3 is I in the complementarity determining region CDR-VL2.

[0042] In one or more embodiments, X2 is H and X3 is V in the complementarity determining region CDR-VL2.

[0043] In one or more embodiments, X2 is H and X3 is L in the complementarity determining region CDR-VL2.

[0044] In one or more embodiments, X2 is N and X3 is I in the complementarity determining region CDR-VL2.

[0045] In one or more embodiments, X2 is N and X3 is V in the complementarity determining region CDR-VL2.

[0046] In one or more embodiments, X2 is N and X3 is L in the complementarity determining region CDR-VL2.

[0047] In one or more embodiments, X1 is I and X2 is I in the complementarity determining region CDR-VL3.

[0048] In one or more embodiments, X1 is I and X2 is V in the complementarity determining region CDR-VL3.

[0049] In one or more embodiments, X1 is I and X2 is L in the complementarity determining region CDR-VL3.

[0050] In one or more embodiments, X1 is V and X2 is I in the complementarity determining region CDR-VL3.

[0051] In one or more embodiments, in the complementarity determining region CDR-VL3, X1 is V and X2 is V.

[0052] In one or more embodiments, X1 is V and X2 is L in the complementarity determining region CDR-VL3.

[0053] In one or more embodiments, X1 is L and X2 is I in the complementarity determining region CDR-VL3.

[0054] In one or more embodiments, X1 is L and X2 is V in the complementarity determining region CDR-VL3.

[0055] In one or more embodiments, X1 is L and X2 is L in the complementarity determining region CDR-VL3.

[0056] In one or more embodiments, the mutation site in each complementarity determining region is any one selected from the following combinations of mutations:

[0057] TIFF0007590964000001.tif243170

[0058] In one or more embodiments, the binding protein comprises at least three CDRs, or the binding protein comprises at least six CDRs.

[0059] In one or more embodiments, the binding protein is a complete antibody including variable and constant regions.

[0060] In one or more embodiments, the binding protein is one of a nanobody, a F(ab')2, a Fab', a Fab, an Fv, a scFv, a diabody, and a minimal recognition unit of an antibody.

[0061] In one or more embodiments, the binding protein comprises light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4, the sequences of which are set forth, in order, in SEQ ID NOs: 1 to 4, and / or heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, the sequences of which are set forth, in order, in SEQ ID NOs: 5 to 8. In one or more embodiments, the binding protein further comprises an antibody constant region sequence.

[0062] In one or more embodiments, the constant region sequence is the sequence of any one of the constant regions selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

[0063] In one or more embodiments, the constant region is derived from a bovine, horse, cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, marten, chicken, duck, goose, turkey, gamecock, or human species.

[0064] In one or more embodiments, the constant region is derived from a mouse. The light chain constant region sequence is shown in SEQ ID NO:9. The heavy chain constant region sequence is shown in SEQ ID NO:10.

[0065] The disclosure further provides an isolated nucleic acid encoding said binding protein.

[0066] The disclosure further provides a vector comprising the nucleic acid.

[0067] The expression vectors of the disclosure are used in transformed host cells, which are encompassed by the disclosure and may be used to propagate the nucleic acid fragments and vectors of the disclosure, or for recombinant production of the polypeptides of the disclosure in cultured cells or cell lines.

[0068] The disclosure further provides a method for producing said binding protein comprising the steps of culturing said host cells in a medium and recovering the produced binding protein from the medium or from the cultured host cells. The present disclosure further provides the use of the binding protein in PCR.

[0069] The disclosure further provides a kit, wherein the kit comprises one or more of the binding protein, the isolated nucleic acid, or the vector.

[0070] The present disclosure further provides a composition comprising a binding protein described in this disclosure and Taq DNA polymerase.

[0071] In one or more embodiments, the composition further comprises four deoxyribonucleoside triphosphates.

[0072] In one or more embodiments, the composition further comprises a primer and / or a probe.

[0073] In one or more embodiments, the composition further comprises MgCl.

[0074] In one or more embodiments, the composition further comprises a nucleic acid as a template.

[0075] The present disclosure further provides a method for amplifying nucleic acid comprising performing hot start PCR using a binding protein described in the present disclosure or a composition described in the present disclosure.

[0076] In one or more embodiments, the hot-start PCR is selected from the group consisting of multiplex PCR, real-time PCR, and real-time quantitative PCR.

[0077] The present disclosure further provides a method for detecting Taq DNA polymerase in a sample, comprising: a) contacting Taq DNA polymerase in the sample with a binding protein of the present disclosure under conditions sufficient to allow an antibody / antigen binding reaction to occur, thereby forming an immune complex; b) detecting the presence of said immune complex, the presence of said complex indicating the presence of said Taq DNA polymerase in said sample.

[0078] In one or more embodiments, the immune complex further comprises a second antibody that binds to the binding protein.

[0079] In one or more embodiments, in step a), the immune complex further comprises a second antibody that binds to the Taq DNA polymerase.

[0080] The disclosure further provides the use of the binding proteins described herein for amplifying nucleic acids. [Brief description of the drawings]

[0081] Next, in order to more clearly explain the technical solutions related to specific embodiments of the present disclosure or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly described. It goes without saying that the drawings described below are some embodiments of the present disclosure, and other drawings can be derived from these drawings by those skilled in the art without performing any novel work. [Figure 1] FIG. 1 is an electrophoretic diagram of a monoclonal antibody of the recombinant anti-Taq DNA polymerase antibody of the present disclosure. [Diagram 2] FIG. 2 is a PCR electrophoretic diagram of Taq DNA polymerase. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0082] The present disclosure will become more readily understood from the following detailed description of certain embodiments of the disclosure and the examples cited therein.

[0083] Before further describing the present disclosure, it should be understood that the present disclosure is not limited to specific embodiments, since the embodiments may take various forms. It should be further understood that the terms used in this specification are for the purpose of describing specific embodiments, and the scope of the present disclosure is limited by the claims, and therefore the terms are not used for the purpose of limitation.

[0084] Unless otherwise defined herein, scientific and technical terms used in this disclosure have the ordinary meanings understood by those skilled in the art. The meaning and scope of the terms should be clear, but in case of risk of ambiguity, the definitions set forth herein take precedence over any dictionary or external definitions. In this application, unless otherwise stated, "or" is used in the sense of "and / or." In addition, the term "comprises" and other forms are used in an open-ended manner.

[0085] In general, the nomenclature and associated techniques used in cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein-nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. Unless otherwise specified, the methods and techniques disclosed herein are generally performed according to conventional methods well known in the art and described in the general and more specific references, which are incorporated herein in their entirety and are considered to be incorporated by reference. Enzymatic reactions and purification techniques are performed according to manufacturer's instructions, practices conventional in the art, or as described herein. The nomenclature, experimental procedures and techniques used in analytical chemistry, organic synthesis, medical and pharmaceutical chemistry referred to in the description herein are well known and commonly used in the art.

[0086] Terms selected for ease of understanding this disclosure have the following definitions.

[0087] The term "amino acid" refers to a naturally occurring or non-naturally occurring carboxyl α-amino acid. As used herein, the term "amino acid" includes naturally occurring and non-naturally occurring amino acids. Naturally occurring amino acids include alanine (three letter abbreviation is A1a, one letter abbreviation is A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine ​​(Cys, c), glutamine (G1n, Q), glutamic acid (G1u, E), glycine (G1y, G), histidine (His, H), isoleucine (I1e, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Va1, V). Non-naturally occurring amino acids include, but are not limited to, α-aminoadipic acid, aminobutyric acid, citrulline, homocitrulline, homoleucine, homoarginine, hydroxyproline, norleucine, pyridylalanine, sarcosine, and the like.

[0088] The term "isolated binding protein" refers to a protein that is not associated with the native binding components with which it is naturally associated because of its derived origin or derivation, is substantially free of other proteins from the same species, is expressed by cells of a different species, or is not found in nature. Thus, a protein that is chemically synthesized or synthesized in a cellular system other than the cell in which it naturally occurs will be "isolated" from its native binding components. A protein may also be substantially free of its native binding components by separation, e.g., protein purification techniques well known in the art.

[0089] The term "isolated binding protein comprising an antigen-binding domain" generally refers to any protein / protein fragment comprising a CDR region. The term "antibody" includes polyclonal antibodies, monoclonal antibodies and antigen-binding fragments of these antibodies, including Fab, F(ab')2, Fd, Fv, scFv, bispecific antibodies, minimal antibody recognition units, and single chain derivatives of these antibodies and fragments. Antibody types are selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD. The term "antibody" also includes naturally occurring and non-naturally occurring antibodies, including, for example, chimeric, bifunctional, and humanized antibodies, and related synthetic isoforms. The term "antibody" is used interchangeably with "immunoglobulin."

[0090] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. The heavy chain variable domain is also called "VH". The light chain variable domain is also called "VL". These domains are generally the most variable parts of the antibody and contain the antigen-binding site. The light or heavy chain variable region is composed of three "complementarity determining regions" or "CDRs" separated by framework regions. The framework regions of an antibody, i.e., the framework regions of the combined light and heavy chain components, serve to position and align the CDRs, which function primarily to bind to antigens.

[0091] As used herein, "framework region," "scaffold region," or "FR" refers to the regions of an antibody variable domain excluding the regions defined as the CDRs. The framework region of each antibody variable domain is further divided into adjacent regions (FR1, FR2, FR3, and FR4) separated by the CDRs.

[0092] Generally, the heavy and light chain variable regions VL / VH may be formed by connecting a combination of CDRs and FRs in the order shown as FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0093] As used herein, the term "purified" or "isolated" in relation to a polypeptide or nucleic acid refers to a polypeptide or nucleic acid that is not in its natural environment or in a natural state. Thus, the term "isolated" includes a polypeptide or nucleic acid that has been removed from its native environment, e.g., the natural environment if it occurs in nature. For example, an isolated polypeptide is usually free of at least certain proteins or other cellular components that are generally associated with or mixed with it or are in solution. Isolated polypeptides include naturally produced polypeptides in a cell lysate, purified or partially purified polypeptides, recombinant polypeptides, polypeptides expressed or secreted by a cell, and polypeptides in a heterologous host cell or culture. When used in relation to a nucleic acid, the term "isolated" or "purified" refers, for example, to the fact that the nucleic acid is not in its natural genome (e.g., in a vector, linked to a promoter as an expression cassette, or artificially introduced into a heterologous host cell).

[0094] The term "bispecific antibody" or "bifunctional antibody" as used herein refers to an artificial hybrid binding protein having two different pairs of heavy / light chains and two different binding sites. Bispecific binding proteins may be produced by a variety of methods, including fusion hybridomas or Fab' fragment joining.

[0095] As used herein, the term "sequence identity" refers to the similarity between at least two different sequences. This percentage identity may be determined by standard algorithms, such as, for example, BLAST (Basic Local Alignment Search Tool), the Needleman et al. algorithm, or the Meyers et al. algorithm. In one or more embodiments, the parameters set may be a Blosum 62 scoring matrix and a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0096] In one or more embodiments, the percentage identity between two amino acid or nucleotide sequences may be determined by the algorithm of Meyers and Miller ((1989) CABIOS 4:11-17), which is already incorporated into the ALIGN program (version 2.0), which uses a PAM120 weighted residual table, a gap length penalty of 12, and a gap penalty of 4. Percentage identity is typically calculated by comparing sequences that are similar in length.

[0097] As used herein, the term "affinity" refers to the binding strength between an antigen or epitope and an antigen-binding domain that binds to a protein or antibody. Affinity may be expressed as a KD value, with a smaller KD value indicating a higher affinity.

[0098] The present disclosure provides an isolated binding protein comprising an antigen-binding domain, the antigen-binding domain comprising at least one complementarity determining region selected from the amino acid sequences below, or having at least 80% sequence identity with a complementarity determining region of the amino acid sequence below, and having a K for Taq DNA polymerase: D ≦8.568×10 -9 It has an affinity of mol / L. The complementarity determining region CDR-VH1 is SV-X1-TF-X2-TYY-X3-Y, where X1 is D, E or N, X2 is S or T, and X3 is I or L; The complementarity determining region CDR-VH2 is G-X1-NPTS-X2-PVF-X3-EK, where X1 is I, V or L, X2 is N or GG, and X3 is D, E or N; The complementarity determining region CDR-VH3 is TRS-X1-X2-RRGYY-X3-DY, where X1 is I, V or L, X2 is I, V or L, and X3 is F or P; The complementarity determining region CDR-VL1 is R-X1-SQDI-X2-NY-X3-N, where X1 is A or G, X2 is N or Q, and X3 is I, V, or L; The complementarity determining region CDR-VL2 is IY-X1-TSRL-X2-SG-X3-P, where X1 is Y or F, X2 is Q, H or N, and X3 is I, V or L; The complementarity determining region CDR-VL3 is QDDT-X1-P-X2-T-X3-G, where X1 is I, V or L, X2 is I, V or L, and X3 is W or F.

[0099] As is well known in the art, both the binding specificity and affinity of an antibody are primarily determined by the CDR sequence, and the amino acid sequence of the non-CDR region can be easily altered by mature techniques and various conventional techniques known in the art to obtain variants with similar biological activity. Thus, the present disclosure includes "functional derivatives" of the binding protein. "Functional derivatives" refer to variants with amino acid substitutions, which retain detectable binding protein activity, preferably antibody activity capable of binding to Taq DNA polymerase. "Functional derivatives" may include "variants" and "fragments," which have the exact same CDR sequence as the binding protein described in the present disclosure and therefore have similar biological activity.

[0100] In one or more embodiments, the antigen binding domain has at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% sequence identity to a complementarity determining region of the amino acid sequence of -9 mol / L, e.g. 8.568×10 -9 mol / L, 5.126×10 -9 mol / L, 3.018×10 -9 mol / L, 2.196×10 -10 mol / L, 3.839×10 -10 mol / L, 4.075×10 -10 mol / L, 6.772 x 10 -10 mol / L, 8.499×10 -10 mol / L, 9.870×10 -10 mol / L, 3.145×10 -11 mol / L, 5.067×10 -11 mol / L, 6.643×10 -11 mol / L, or 1.328 x 10 -11 mol / L≦KD≦8.568×10 -9 mol / L, or 1.328 x 10 -11 mol / L≦KD≦9.870×10 -10 mol / L or KD≦5.126×10 -9 mol / L, 3.018×10 -9 mol / L, 2.196×10 -10 mol / L, 3.839×10 -10 mol / L, 4.075×10 -10 mol / L, 6.772 x 10 -10 mol / L, 8.499×10 -10 mol / L, 9.870×10 -10 mol / L, 3.145×10 -11 mol / L, 5.067×10-11 mol / L or 6.643 x 10 -11 It has an affinity of mol / L.

[0101] However, affinity is measured according to the methods of the present disclosure.

[0102] In one or more embodiments, In the complementarity determining region CDR-VH1, X3 is I; In the complementarity determining region CDR-VH2, X3 is N; In the complementarity determining region CDR-VH3, X3 is F; In the complementarity determining region CDR-VL1, X1 is A; In the complementarity determining region CDR-VL2, X1 is Y; In said complementarity determining region CDR-VL3, X3 is F.

[0103] In one or more embodiments, X1 is D and X2 is S in the complementarity determining region CDR-VH1.

[0104] In one or more embodiments, X1 is E and X2 is S in the complementarity determining region CDR-VH1.

[0105] In one or more embodiments, X1 is N and X2 is S in the complementarity determining region CDR-VH1.

[0106] In one or more embodiments, X1 is D and X2 is T in the complementarity determining region CDR-VH1.

[0107] In one or more embodiments, X1 is E and X2 is T in the complementarity determining region CDR-VH1.

[0108] In one or more embodiments, X1 is N and X2 is T in the complementarity determining region CDR-VH1.

[0109] In one or more embodiments, X1 is I and X2 is N in the complementarity determining region CDR-VH2.

[0110] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is I and X2 is GG.

[0111] In one or more embodiments, X1 is V and X2 is N in the complementarity determining region CDR-VH2.

[0112] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is V and X2 is GG.

[0113] In one or more embodiments, X1 is L and X2 is N in the complementarity determining region CDR-VH2.

[0114] In one or more embodiments, in the complementarity determining region CDR-VH2, X1 is L and X2 is GG.

[0115] In one or more embodiments, X1 is I and X2 is I in the complementarity determining region CDR-VH3.

[0116] In one or more embodiments, X1 is I and X2 is V in the complementarity determining region CDR-VH3.

[0117] In one or more embodiments, X1 is I and X2 is L in the complementarity determining region CDR-VH3.

[0118] In one or more embodiments, X1 is V and X2 is I in the complementarity determining region CDR-VH3.

[0119] In one or more embodiments, in the complementarity determining region CDR-VH3, X1 is V and X2 is V.

[0120] In one or more embodiments, X1 is V and X2 is L in the complementarity determining region CDR-VH3.

[0121] In one or more embodiments, X1 is L and X2 is I in the complementarity determining region CDR-VH3.

[0122] In one or more embodiments, X1 is L and X2 is V in the complementarity determining region CDR-VH3.

[0123] In one or more embodiments, X1 is L and X2 is L in the complementarity determining region CDR-VH3.

[0124] In one or more embodiments, X2 is N and X3 is I in the complementarity determining region CDR-VL1.

[0125] In one or more embodiments, X2 is N and X3 is V in the complementarity determining region CDR-VL1.

[0126] In one or more embodiments, X2 is N and X3 is L in the complementarity determining region CDR-VL1.

[0127] In one or more embodiments, X2 is Q and X3 is I in the complementarity determining region CDR-VL1.

[0128] In one or more embodiments, X2 is Q and X3 is V in the complementarity determining region CDR-VL1.

[0129] In one or more embodiments, X2 is Q and X3 is L in the complementarity determining region CDR-VL1.

[0130] In one or more embodiments, X2 is Q and X3 is I in the complementarity determining region CDR-VL2.

[0131] In one or more embodiments, X2 is Q and X3 is V in the complementarity determining region CDR-VL2.

[0132] In one or more embodiments, X2 is Q and X3 is L in the complementarity determining region CDR-VL2.

[0133] In one or more embodiments, X2 is H and X3 is I in the complementarity determining region CDR-VL2.

[0134] In one or more embodiments, X2 is H and X3 is V in the complementarity determining region CDR-VL2.

[0135] In one or more embodiments, X2 is H and X3 is L in the complementarity determining region CDR-VL2.

[0136] In one or more embodiments, X2 is N and X3 is I in the complementarity determining region CDR-VL2.

[0137] In one or more embodiments, X2 is N and X3 is V in the complementarity determining region CDR-VL2.

[0138] In one or more embodiments, X2 is N and X3 is L in the complementarity determining region CDR-VL2.

[0139] In one or more embodiments, X1 is I and X2 is I in the complementarity determining region CDR-VL3.

[0140] In one or more embodiments, X1 is I and X2 is V in the complementarity determining region CDR-VL3.

[0141] In one or more embodiments, X1 is I and X2 is L in the complementarity determining region CDR-VL3.

[0142] In one or more embodiments, X1 is V and X2 is I in the complementarity determining region CDR-VL3.

[0143] In one or more embodiments, in the complementarity determining region CDR-VL3, X1 is V and X2 is V.

[0144] In one or more embodiments, X1 is V and X2 is L in the complementarity determining region CDR-VL3.

[0145] In one or more embodiments, X1 is L and X2 is I in the complementarity determining region CDR-VL3.

[0146] In one or more embodiments, X1 is L and X2 is V in the complementarity determining region CDR-VL3.

[0147] In one or more embodiments, X1 is L and X2 is L in the complementarity determining region CDR-VL3.

[0148] In one or more embodiments, the mutation site in each complementarity determining region is any one selected from the following combinations of mutations: TIFF0007590964000002.tif243170

[0149] In one or more embodiments, each X1 occurring in the six CDR regions of the binding proteins described herein independently represents an amino acid as defined herein; each X2 occurring in the six CDR regions of the binding proteins described herein independently represents an amino acid as defined herein; and each X3 occurring in the six CDR regions of the binding proteins described herein independently represents an amino acid as defined herein.

[0150] In one or more embodiments, the binding protein comprises at least three CDRs, or the binding protein comprises at least six CDRs.

[0151] In one or more embodiments, the binding protein is a complete antibody including variable and constant regions.

[0152] In one or more embodiments, the binding protein is one of a nanobody, a F(ab')2, a Fab', a Fab, an Fv, a scFv, a diabody, and a minimal recognition unit of an antibody.

[0153] In one or more embodiments, the binding protein comprises light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4, the sequences of which are set forth, in order, in SEQ ID NOs: 1 to 4, and / or heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, the sequences of which are set forth, in order, in SEQ ID NOs: 5 to 8.

[0154] In one or more embodiments, the binding protein further comprises an antibody constant region sequence.

[0155] In one or more embodiments, the constant region sequence is the sequence of any one of the constant regions selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

[0156] In one or more embodiments, the constant region is derived from a bovine, horse, cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, marten, chicken, duck, goose, turkey, gamecock, or human species.

[0157] In one or more embodiments, the constant region is derived from a mouse. The light chain constant region sequence is shown in SEQ ID NO:9. The heavy chain constant region sequence is shown in SEQ ID NO:10.

[0158] The disclosure further provides an isolated nucleic acid encoding said binding protein.

[0159] As used herein, nucleic acids include conservatively substituted variants thereof (e.g., degenerate codon substitutions) and complementary sequences. The term "nucleic acid" is synonymous with "polynucleotide" and includes genes, cDNA molecules, mRNA molecules, and fragments thereof, such as oligonucleotides.

[0160] The disclosure further provides a vector comprising the nucleic acid.

[0161] Here, the nucleic acid sequence is operably linked to at least one regulatory sequence. "Operably linked" means that the coding sequence is connected to a regulatory sequence in such a way that the coding sequence can be expressed. The regulatory sequence is selected to direct expression of the desired protein in an appropriate host cell and includes promoters, enhancers and other expression control elements.

[0162] As used herein, vector also refers to a molecule or reagent that contains the disclosed nucleic acid or a fragment thereof, carries genetic information, and delivers the genetic information to a cell. Exemplary vectors include plasmids, viruses, bacteriophages, cosmids, and minichromosomes. A vector may be a cloning vector (a vector that can be used to transfer genetic information to a cell, allowing the cell to grow and select the cell in which the genetic information is present or absent) or an expression vector (a vector that contains the necessary genetic elements to allow the vector's genetic information to be expressed in a cell). Thus, a cloning vector contains a selectable marker and an origin of replication that matches the cell type addressed by the cloning vector, and an expression vector contains the necessary regulatory elements to affect expression in a given target cell.

[0163] The nucleic acid of the present disclosure or a fragment thereof can be inserted into an appropriate vector to form a cloning vector or an expression vector carrying the nucleic acid fragment of the present disclosure. Such new vectors are also included in the present disclosure. The vectors include plasmids, bacteriophages, cosmids, mini-chromosomes, viruses, or naked DNA that is only transiently expressed in certain cells. The cloning and expression vectors of the present disclosure are autonomously replicating, providing high copy numbers for subsequent cloning of high level expression or high level replication. The expression vector includes a promoter that drives expression of the nucleic acid fragment of the present disclosure, and may include a nucleic acid sequence that optionally encodes a signal peptide that allows the peptide expression product to be secreted or integrated into a membrane, the nucleic acid fragment of the present disclosure, and optionally a nucleic acid sequence that encodes a terminator. The expression vector is engineered in a production strain or cell line, and when the vector is introduced into a host cell, it may or may not be integrated into the host cell genome. The vector generally includes a replication site and a marker sequence that provides phenotypic selection in transformed cells.

[0164] The expression vectors of the present disclosure are used in transformed host cells. Such transformed cells are included in the present disclosure and may be cultured cells or cell lines used to propagate the nucleic acid fragments and vectors of the present disclosure or used for recombinant production of the polypeptides of the present disclosure. Transformed cells of the present disclosure include microorganisms, such as bacteria (E. coli, Bacillus spp., etc.). Further host cells include multicellular organisms, such as fungi, insect cells, plant cells, or cells derived from mammals, preferably cells derived from mammals, such as CHO cells. The transformed cells are capable of replicating the nucleic acid fragments of the present disclosure. During recombinant production of the peptide combinations of the present disclosure, the expression products are secreted into the medium or incorporated on the surface of the transformed cells.

[0165] The disclosure further provides a method for producing said binding protein comprising the steps of culturing said host cells in a medium and recovering the produced binding protein from the medium or from the cultured host cells.

[0166] The method may, for example, involve transfecting a host cell with a nucleic acid vector encoding at least a portion of the binding protein and culturing the host cell under appropriate conditions to express the binding protein. The host cell may be transfected with one or more expression vectors, which may contain DNA encoding at least a portion of the binding protein, either alone or in combination. The binding protein may be isolated from culture medium or cell lysates using conventional protein and peptide purification techniques, including ammonium sulfate precipitation, chromatography (e.g., ion exchange, gel filtration, affinity chromatography, etc.), and / or electrophoresis.

[0167] Construction of suitable vectors containing the desired coding and control sequences may be accomplished using standard ligation and restriction techniques well known in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides may be cleaved, tailed, and religated to obtain the desired configuration. Variants of the disclosure may be obtained by introducing mutations into the coding sequence in any manner, including deletions, insertions, substitutions, and the like.

[0168] The present disclosure further provides antibodies that react with epitopes of Taq DNA polymerase, including monoclonal and polyclonal antibodies. The antibodies may comprise the entire binding protein, or fragments or derivatives thereof. Antibodies comprising the entire binding protein or a portion thereof are preferred.

[0169] The present disclosure further provides the use of the binding protein in PCR.

[0170] The disclosure further provides a kit, wherein the kit comprises one or more of the binding protein, the isolated nucleic acid, or the vector.

[0171] The present disclosure further provides a composition comprising a binding protein described in this disclosure and Taq DNA polymerase.

[0172] In one or more embodiments, the composition further comprises four deoxyribonucleoside triphosphates.

[0173] In one or more embodiments, the composition further comprises a primer and / or a probe.

[0174] In one or more embodiments, the composition further comprises MgCl.

[0175] In one or more embodiments, the composition further comprises a nucleic acid as a template.

[0176] The present disclosure further provides a method for amplifying nucleic acid comprising performing hot start PCR using a binding protein described in the present disclosure or a composition described in the present disclosure.

[0177] In one or more embodiments, the hot-start PCR is selected from the group consisting of multiplex PCR, real-time PCR, and real-time quantitative PCR.

[0178] As used herein, the term "hot start PCR" refers to PCR in which Taq DNA polymerase only plays its role when the sample temperature is at least above a predetermined temperature, thereby increasing the specificity of the reaction and avoiding non-specific amplification of nucleic acids.

[0179] The present disclosure further provides a method for detecting Taq DNA polymerase in a sample, comprising: a) contacting Taq DNA polymerase in the sample with a binding protein of the present disclosure under conditions sufficient to allow an antibody / antigen binding reaction to occur, thereby forming an immune complex; b) detecting the presence of said immune complex, the presence of said complex indicating the presence of said Taq DNA polymerase in said sample.

[0180] In one or more embodiments, the immune complex further comprises a second antibody that binds to the binding protein. In one or more embodiments, in step a), the immune complex further comprises a second antibody that binds to the Taq DNA polymerase.

[0181] The disclosure further provides the use of the binding proteins described herein for amplifying nucleic acids.

[0182] Next, some examples are given to illustratively explain the present disclosure, but the scope of the present disclosure is not limited thereto.

[0183] Example 1 In this example, restriction enzymes and Prime Star DNA polymerase were purchased from Takara Co., Ltd. MagExtractor-RNA extraction kit was purchased from TOYOBO Co., Ltd. SMARTERTM RACE cDNA Amplification Kit was purchased from Takara Co., Ltd. pMD-18T vector was purchased from Takara Co., Ltd. Plasmid extraction kit was purchased from Tengen Biochemical Technology Co., Ltd. Primer synthesis and gene sequencing were performed by Invitrogen Co., Ltd. The hybridoma cell line secreting anti-TAQ 2C7 monoclonal antibody was an existing hybridoma cell line that was resuscitated for use.

[0184] 1. Primer Heavy and light chain 5' amplification RACE primers: SMARTER II A Oligonucleotides: 5'-AAGCAGTGGTATCAACGCAGAGTACXXXXX-3', 5'-RACE CDS primer (5'-CDS): 5'-(T) 25 VN-3' (N=A, C, G or T, V=A, G or C), Universal primer A mix (UPM): 5'-CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3', Nested universal primer A (NUP): 5'-AAGCAGTGGTATCAACGCAGAGT-3'; mIg-KR:5'-CTAACACTCATTCCTGTTGAAGCTCTTGACAAT-3', mIg-HR:5'-TCATTTACCAGGAGAGTGGGAGAGGC-3'.

[0185] 2. Gene cloning and sequencing of antibody variable regions RNA was extracted from a hybridoma cell line secreting the Anti-Taq 2C7 cloned antibody and analyzed using SMARTER TM First-strand cDNA was synthesized using the RACE cDNA Amplification Kit and the SMARTER II A oligonucleotide and 5'-CDS primer in the kit, and the first-strand cDNA product was obtained and used as a PCR amplification template. The light chain gene was amplified with the universal primer A mix (UPM), nested universal primer A (NUP), and mKR primer, and the heavy chain gene was amplified with the universal primer A mix (UPM), nested universal primer A (NUP), and mHR primer. The light chain primer pair gave a target band of about 0.7 KB, and the heavy chain primer pair gave a target band of about 1.4 KB. The product was purified and recovered by agarose gel electrophoresis, and the A-tailing reaction of the product was performed using rTaq DNA polymerase, and then inserted into the pMD-18T vector and transformed into DH5α competent cells. When colonies were observed, the heavy and light chain genes were cloned, and four clones each were sequenced by Invitrogen Co., Ltd.

[0186] 3. Sequence analysis of the variable region genes of Anti-Taq 2C7 antibody The gene sequences determined as described above were entered into the IMGT antibody database and analyzed using the software VNTI11.5. It was found that both the genes amplified with the heavy chain and light chain primer pairs were correct. Of these, the gene fragment amplified with the light chain had a VL gene sequence of 378 bp belonging to the VkII gene family preceded by a 57 bp leader peptide sequence, and the gene fragment amplified with the heavy chain primer pair had a VH gene sequence of 417 bp belonging to the VH1 gene family preceded by a 57 bp leader peptide sequence.

[0187] 4. Construction of Recombinant Antibody Expression Plasmids pcDNA TM 3.4 TOPO® vector is a recombinant antibody eukaryotic expression vector constructed, which has polyclonal enzyme cleavage sites such as HindIII, BamHI, EcoRI, etc. introduced into it, and is named pcDNA 3.4A expression vector, hereinafter referred to as 3.4A expression vector. Based on the gene sequence determination results of the antibody variable region of pMD-18T, primers specific to the VL and VH genes of Anti-TAQ 2C7 antibody are designed, which have HindIII and EcoRI enzyme cleavage sites and protective bases at both ends, respectively. The primers are as follows:

[0188] Anti-Taq 2C7-HF:5'-CCCAAGCTTGCCACCATGGGATGGAGCTATATCATCCTC-3', Anti-Taq 2C7-HR: 5'-CCCGAATTCTCATTATTTACCAGGAGAGTGGGAGAGGCTCTTCTC-3', Anti-Taq 2C7-LF:5'-CCCAAGCTTGCCACCATGTCCTCTGCTCAGTTCCTTGGTCTC-3', Anti-Taq 2C7-LR: 5'-CCCGAATTCTCATTAACACTCATTCCTGTTGAAGCTCTTGACAA-3'.

[0189] A 0.75 KB light chain gene fragment and a 1.42 KB heavy chain gene fragment were obtained by PCR amplification. The heavy and light chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was double-digested with HindIII / EcoRI. The fragments and vectors were purified and recovered, and then the heavy and light chain genes were ligated into the 3.4A expression vector to obtain the heavy and light chain recombinant expression plasmids, respectively.

[0190] 5. Stable cell line screening 5.1 Transient transfection of CHO cells with recombinant antibody expression plasmids and determination of expression plasmid activity The plasmid was diluted to 400ng / ml with ultrapure water and incubated at 1.43×10 7 The plasmid was adjusted to cells / ml and placed in a centrifuge tube, 100 μL of plasmid and 700 μl of cells were mixed, then transferred to an electroporation cup and electroporation was performed. Samples were taken and counted on the 3rd, 5th, and 7th days, and recovered and detected on the 7th day.

[0191] Taq enzyme was diluted to a given concentration with coating solution, and 100 μL per well was left to stand overnight at 4°C. The next day, the plate was washed twice with washing solution and tapped dry. Blocking solution (20% BSA + 80% PBS) was added at 120 μL per well, and the plate was left to stand at 37°C for 1 hour, and tapped dry. Diluted cell supernatant was added at 100 μL / well and left to stand at 37°C for 30 minutes (some supernatants for 1 hour). The plate was washed five times with washing solution and tapped dry. Goat anti-mouse IgG-HRP was added at 100 μL per well and left to stand at 37°C for 30 minutes. The plate was washed five times with washing solution and tapped dry. Color development solution A (50 μL / well) and color development solution B (50 μL / well) were added and left to stand for 10 minutes. Stop solution was added at 50 μL / well. The OD values ​​were read in a microplate reader at 450 nm (reference 630 nm). The results showed that after 1000-fold dilution of the cell supernatant, the reaction OD was still greater than 1.0, while the reaction OD of the wells without cell supernatant was less than 0.1, indicating that the antibodies produced after transient transfection of the plasmids were active against Taq enzyme.

[0192] 5.2 Recombinant antibody expression plasmid linearization Prepare the following reagents: 50 μl buffer, 100 μg DNA / tube, 10 μl Puv I enzyme, supplement with sterile water to 500 μl, digest overnight in a 37°C water bath, extract first with an equal volume of phenol / chloroform / isoamyl alcohol 25:24:1 (bottom layer), then with an equal volume of chloroform (aqueous phase), precipitate on ice with 0.1 volume of 3M sodium acetate and 2 volumes of ethanol (aqueous phase), rinse the precipitate with 70% ethanol to remove the organic solvent, redissolve in an appropriate amount of sterile water once the ethanol has completely evaporated, and finally measure the concentration.

[0193] 5.3 Stable transfection of recombinant antibody expression plasmids and pressure screening of stable cell lines The plasmid was diluted to 400ng / ml with ultrapure water and incubated at 1.43×10 7The cells were mixed with 100 μl of plasmid and 700 μl of cells, then transferred to an electroporation cup, electroporated, and counted the next day. The cells were pressurized and cultured in a 96-well plate containing 25 μmol / L MSX for approximately 25 days.

[0194] The wells were observed under a microscope, the cloning wells in which cells were found were marked, and the confluence was recorded. The culture supernatant was obtained and the samples were detected. The cell line with the higher antibody concentration and relative concentration was selected and transferred to a 24-well plate, and about 3 days later, it was transferred to a 6-well plate. After 3 days, the bacterial strain was preserved and batch cultured, and the cell density was adjusted to 0.5 × 10 6 The cell density was adjusted to 0.3 × 10 cells / ml, and 2.2 ml was taken and cultured in batches. 6 When the antibody concentration reached 1.0 cells / ml, 2 ml was taken and the bacterial strain was preserved. The supernatant was batch cultured in a 6-well plate for 7 days, and the cell line with the smaller antibody concentration and cell diameter was selected and transferred to the TPP, where the bacterial strain was preserved and passaged.

[0195] 6. Recombinant Antibody Production 6.1 Cell expansion culture After resuscitation, the cells were first cultured in a 125ml shake flask, with an inoculation volume of 30ml and 100% Dynamis medium in a shaker at 120 revolutions per minute, 37°C and 8% carbon dioxide. After 72 hours of culture, the cells were inoculated and expanded at an inoculation density of 500,000 cells / ml, with the expansion volume calculated according to the production volume and 100% Dynamis medium in the medium. Then, the cells were expanded once every 72 hours. When the cell volume met the production needs, the inoculation density was precisely limited to about 500,000 cells / ml for production.

[0196] 6.2 Shake flask production and purification Shake flask parameters: 120 revolutions per minute, temperature 37°C, and 8% carbon dioxide. Feed supplementation: After 72 hours of culture in shake flasks, feed was supplemented daily and HyClone was used. TM Cell Boost TMFeed 7a was fed daily at 3% of the initial culture volume, and Feed 7b was fed daily at 1 / 1000 of the initial culture volume, and supplementation continued until day 12 (supplementation on day 12). On day 6, glucose was supplemented at 3 g / L. Harvested on day 13. Affinity purification was performed using a protein A affinity chromatography column. 4 μg of purified antibody was subjected to reducing SDS-PAGE, with 4 μg of exogenous control antibody as a control, and the electropherogram is shown in FIG. 1. After reducing SDS-PAGE, two bands were observed, one with Mr 50 KD (heavy chain) and sequence shown in SEQ ID NO: 11, and the other with Mr 28 KD (light chain) and sequence shown in SEQ ID NO: 12.

[0197] Example 2 The antibody sample 1 obtained in Example 1 (having a heavy chain whose sequence is shown in SEQ ID NO: 11 and a light chain whose sequence is shown in SEQ ID NO: 12) has the ability to bind to Taq DNA polymerase, but the affinity and antibody activity are not favorable, so the applicant mutated the light chain CDR and heavy chain CDR of the antibody.

[0198] Analysis revealed that the heavy chain complementarity determining region (WT) was as follows: CDR-VH1 is SVD(X1)-TFS(X2)-TYYL(X3)-Y, CDR-VH2 is GV(X1)-NPTSN(X2)-PVFD(X3)-EK, CDR-VH3 is TRSI(X1)-L(X2)-RRGYYP(X3)-DY.

[0199] The complementarity determining regions of the light chain are as follows: CDR-VL1 is RG(X1)-SQDIQ(X2)-NYV(X3)-N, CDR-VL2 is IYF(X1)-TSRLQ(X2)-SGI(X3)-P, CDR-VL3 is QDDTI(X1)-PV(X2)-TW(X3)-G; However, X1, X2, and X3 are all mutation sites.

[0200] TIFF0007590964000003.tif47170

[0201] After the mutation, the activity of the antibody was detected by diluting Taq DNA polymerase to a predetermined concentration in the coating solution, and then storing it at 4°C overnight at 100 μL per well. The next day, the plate was washed twice with the washing solution and tapped dry. Blocking solution (20% BSA + 80% PBS) was added at 120 μL per well, and the plate was stored at 37°C for 1 hour, and then tapped dry. The diluted Taq monoclonal antibody was added at 100 μL / well, and the plate was stored at 37°C for 30 minutes (1 hour for some of the supernatant). The plate was washed five times with the washing solution and tapped dry. Goat anti-mouse IgG-HRP was added at 100 μL per well, and the plate was stored at 37°C for 30 minutes. The plate was washed five times with the washing solution and tapped dry. Chromogen solution A (50 μL / well) and chromogen solution B (50 μL / well) were added, and the plate was stored for 10 minutes. Stop solution was added at 50 μL / well. OD values ​​were read at 450 nm (reference 630 nm) in a microplate reader.

[0202] Some results are as follows: TIFF0007590964000004.tif61170

[0203] Affinity analysis: For the AMC sensor, the antibody was diluted to 10 μg / ml in PBST, and Taq DNA polymerase was gradient diluted in PBST as follows: 1000 nmol / ml, 500 nmol / ml, 250 nmol / ml, 125 nmol / ml, 62.5 nmol / ml, 31.3 nmol / ml, 15.6 nmol / ml, 0 nmol / ml.

[0204] Execution process: equilibration with buffer 1 (PBST) for 60 seconds, antibody solidification with antibody solution for 300 seconds, incubation with buffer 2 (PBST) for 180 seconds, binding with antigen solution for 420 seconds, dissociation with buffer 2 for 1200 seconds, then resuscitating the sensor with 10 mM GLY solution at pH 1.69 and buffer 3, and outputting the data. KD represents the equilibrium dissociation constant, i.e., affinity, Kon represents the binding rate, and Kdis represents the dissociation rate.

[0205] TIFF0007590964000005.tif47170

[0206] As can be seen from Tables 2 and 3, Mutation 1 has the highest activity and the best affinity, so Mutation 1 was used as the framework sequence to screen for high-potency mutation sites (after screening, it was ensured that the antibody activity was close to Mutation 1, and the antibody activity was ±10%), and some of the results are as follows:

[0207] TIFF0007590964000006.tif248170

[0208] The method of affinity analysis was the same as above, and the results are shown in Table 5.

[0209] TIFF0007590964000007.tif249170

[0210] As can be seen from Table 5, the mutation sites shown in Table 4 do not significantly affect the affinity of the antibody.

[0211] To verify the above results, the above experiment was repeated using WT as the framework sequence to verify the affinity of the mutation sites. Some of the results are as follows:

[0212] TIFF0007590964000008.tif73170

[0213] TIFF0007590964000009.tif70170

[0214] Analysis of Tables 6 and 7 revealed that the mutation sites shown in Table 6 also do not significantly affect the affinity of the antibody.

[0215] After modification with an antibody, the Taq DNA polymerase of the present disclosure has its enzymatic activity blocked at temperatures below 70°C, dissociated at temperatures above 70°C, and completely dissociated at 95°C in just 1 to 3 minutes, releasing the enzymatic active components.

[0216] Under the same conditions, specificity detection was performed for Taq DNA polymerase with and without antibody modification, and the results are shown in the PCR electrophoresis diagrams in Figure 2, where 1 is Taq DNA polymerase (without antibody modification), 2 and 4 are Taq DNA polymerase modified with mutation 1 antibody, and 3 and 5 are Taq DNA polymerase modified with WT antibody. Analysis of the results shows that the amplification specificity of the antibody-modified TAQ enzyme is obviously improved. Analysis of the non-specific bands appearing in each lane shows that the specificity of Taq DNA polymerase modified with mutation 1 antibody is slightly better than that of Taq DNA polymerase modified with WT antibody. In the present disclosure, the binding stability, rapid activation, and corresponding pH range of the antibody and Taq DNA polymerase were detected for the combinations of mutations in Table 4, and all of them had good effects, indicating that the anti-Taq DNA polymerase antibody of the present disclosure can be expected to be used for molecular detection.

[0217] It should be noted that the above embodiments are for illustrating the technical solutions of the present disclosure without any limitation. Although the above embodiments are used to describe the present disclosure in detail, those skilled in the art can still make modifications to the technical solutions described in the above embodiments, or make equivalent replacements for some or all of the technical features. Such modifications or replacements do not deviate from the spirit of the technical solutions and the scope of the technical solutions of the embodiments of the present disclosure. [Industrial Applicability]

[0218] The binding protein of the present disclosure specifically binds to Taq enzyme to form an antibody-enzyme complex, which can effectively block the activity of Taq DNA polymerase at room temperature, and at high temperatures, the complex dissociates to release active Taq DNA polymerase for PCR amplification. The formation of primer dimers is effectively avoided, the amplification of non-specific products is mitigated, and the long-term stability of Taq DNA polymerase is improved. The binding protein of the present disclosure can be widely used in various hot-start PCRs.

Claims

1. An isolated binding protein comprising an antigen-binding domain of an anti-Taq DNA polymerase, The antigen-binding domain comprises six complementarity-determining regions selected from the following amino acid sequences: the complementarity determining region CDR-VH1 is S-V-X1-T-F-X2-T-Y-Y-X3-Y, where X1 is D, E or N, X2 is S or T and X3 is I; the complementarity determining region CDR-VH2 is G-X1-N-P-T-S-X2-P-V-F-X3-E-K, where X1 is I, V or L, X2 is N or GG and X3 is N; The complementarity determining region CDR-VH3 is T-R-S-X1-X2-R-RG-Y-Y-X3-DY, where X1 is I, V or L, X2 is I, V or L and X3 is F; the complementarity determining region CDR-VL1 is R-X1-S-Q-D-I-X2-N-Y-X3-N, where X1 is A, X2 is N or Q, and X3 is I, V, or L; the complementarity determining region CDR-VL2 is I-Y-X1-T-S-R-L-X2-S-G-X3-P, where X1 is Y, X2 is Q, H or N, and X3 is I, V or L; the complementarity determining region CDR-VL3 is Q-D-D-T-X1-P-X2-T-X3-G, where X1 is I, V or L, X2 is I, V or L, and X3 is F; The mutation sites in the six complementarity determining regions are any one of the following combinations of mutations: The binding protein is characterized in that it comprises light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4, the sequences of which are set forth in SEQ ID NOs: 1 to 4, in that order, and / or heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, the sequences of which are set forth in SEQ ID NOs: 5 to 8, in that order.

2. The binding protein of claim 1, wherein the binding protein is one of F(ab')2, Fab', Fab, Fv, scFv, a bispecific antibody, and an antibody minimal recognition unit.

3. The binding protein of claim 1 , further comprising an antibody constant region sequence.

4. 4. The binding protein of claim 3, wherein the constant region sequence is a sequence of any one of the constant regions selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

5. 4. The binding protein of claim 3, wherein the constant region is derived from a bovine, horse, cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, marten, chicken, duck, goose, turkey, gamecock, or human species.

6. the constant region is derived from a mouse, The light chain constant region sequence is shown in SEQ ID NO:

9. The binding protein of claim 5, wherein the heavy chain constant region sequence is set forth in SEQ ID NO:

10.

7. An isolated nucleic acid encoding a binding protein according to any one of claims 1 to 6.

8. A vector comprising the nucleic acid of claim 7.

9. A host cell comprising a nucleic acid according to claim 7 or a vector according to claim 8.

10. 10. A method for producing a binding protein according to any one of claims 1 to 6, comprising the steps of culturing a host cell according to claim 9 in a medium and recovering the produced binding protein from the medium or from the cultured host cell.

11. Use of the binding protein according to any one of claims 1 to 6 in PCR.

12. A kit comprising one or more of the binding protein according to any one of claims 1 to 6, the isolated nucleic acid according to claim 10, or the vector according to claim 11.

13. A composition comprising the binding protein of any one of claims 1 to 6 and Taq DNA polymerase.

14. In addition, four deoxyribonucleoside triphosphates, primers, probes, MgCl 2 or the composition of claim 13, comprising a nucleic acid as a template.

15. A method for amplifying nucleic acid, comprising carrying out hot start PCR using the binding protein according to any one of claims 1 to 6 or the composition according to claim 13 or 14.

16. 16. The method of claim 15, wherein the hot start PCR is selected from the group consisting of multiplex PCR, real-time PCR, and real-time quantitative PCR.

17. Use of a binding protein according to any one of claims 1 to 6 for amplifying nucleic acids.

Citation Information

Patent Citations

  • Warm starting TaqDNA polymerase and its preparation method and application

    CN107828755A

  • Mixed type hot-start DNA polymerase composition, PCR amplification kit, and applications thereof

    CN108546749A